Vertex raises 2026 revenue guidance after second-quarter sales rise 12%

Vertex reported second-quarter 2026 revenue of $3.33 billion, up 12% from a year earlier, with GAAP net income of $1.10 billion, or $4.31 per diluted share; CASGEVY revenue reached $76 million and JOURNAVX revenue was $50 million. The company raised its full-year 2026 revenue guidance to $13.1 billion-$13.2 billion from $12.95 billion-$13.1 billion and said it expects to acquire Crinetics Pharmaceuticals for $85 per share in cash, or about $10.0 billion, with closing anticipated in the third quarter of 2026.